# About Medicinal Sermorelin: An Independent Research Digest

> Medicinal Sermorelin is an independent editorial project publishing cited summaries of the peer-reviewed sermorelin (GHRH(1-29)) literature. Not a clinic, not a vendor, no medical advice and nothing for sale.

An independent editorial brief on the GHRH(1-29) secretagogue literature — what the studies measured, graded honestly, cited to source.

## What this site is

Medicinal Sermorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on **sermorelin** — the GHRH(1-29) growth-hormone secretagogue. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site reads the literature the way a research-intelligence brief reads a record: the headline finding first, the supporting study disclosed beneath, and the evidence graded — strong where the data is strong (pediatric growth hormone deficiency), limited where it thins out (long-term adult anti-aging use). Every quantitative claim on the site carries a citation to a named, dated study.

## What the name means

The word "medicinal" in this domain is editorial framing, not a service claim. It signals the register we write in — a sober, clinical-intelligence reading of the evidence — not the existence of a clinic, a pharmacy, or a prescription service. We do not diagnose, treat, consult, or dispense. Sermorelin's regulatory history is part of the record we cover: it was a formerly FDA-approved prescription drug for growth hormone deficiency in children, withdrawn from the US market in 2008 for commercial reasons, and is now prepared by compounding pharmacies as a Category 1 503A bulk substance. We report that status; we are not part of it.

## How we handle the evidence

We lead with what was measured and attribute it afterward. We distinguish carefully between findings for sermorelin itself and findings for related analogs such as tesamorelin or CJC-1295, because conflating them is the most common error in popular summaries. We flag the gaps as prominently as the results — the limited long-term adult data, the theoretical oncologic consideration of chronically raising GH and IGF-1, and the fact that anti-aging marketing outpaces the evidence. Where the research is computational or hypothesis-generating, we say so rather than dressing it as clinical proof. The goal is a digest a careful reader can trust and verify.

---

A confidence-graded intelligence brief on the GHRH(1-29) secretagogue record — each figure scored against its study, the pediatric-growth evidence held apart from the limited adult anti-aging data and the formerly-approved-now-compounded status stated plainly; no clinic behind the console and nothing here dosed, prescribed, or sold.